BNP Paribas Acquires 1,410 Shares of Zoetis Inc. (NYSE:ZTS)

BNP Paribas lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 22.4% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 7,707 shares of the company’s stock after acquiring an additional 1,410 shares during the quarter. BNP Paribas’ holdings in Zoetis were worth $1,497,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new stake in Zoetis during the 3rd quarter valued at $31,000. First Personal Financial Services bought a new stake in Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis during the 3rd quarter valued at $33,000. Quarry LP increased its position in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. Finally, Fortitude Family Office LLC increased its position in Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after purchasing an additional 222 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on ZTS. Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, BTIG Research boosted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Stock Up 0.6 %

NYSE:ZTS opened at $176.74 on Thursday. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The firm’s 50-day moving average price is $184.51 and its 200-day moving average price is $180.81. The company has a market capitalization of $79.74 billion, a PE ratio of 33.22, a P/E/G ratio of 2.70 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the firm posted $1.36 EPS. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, equities analysts predict that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is 32.52%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.